Case Study: Fujitsu achieves secure collaboration for drug discovery with Mattermost

Fujitsu Customers with Biodrug Design Accelerator (BDA) use Mattermost to power secure collaboration

Fujitsu, a global information and communications technology corporation, needed a secure collaboration solution for its Biodrug Design Accelerator (BDA) platform. The challenge was to enable real-time information sharing for pharmaceutical researchers while ensuring the highest levels of data security for sensitive R&D information, which often required an on-premises solution.

Fujitsu implemented the Mattermost collaboration platform, which was self-hosted to meet strict data control requirements. The solution integrated with the BDA via Mattermost's API, consolidating drug design information and messaging onto a single screen. This increased operational efficiency, accelerated onboarding for new team members, and provided Fujitsu with complete control to rapidly investigate and resolve any issues.

Fujitsu